BSE Live
Feb 13, 16:01Prev. Close
865.60
Open Price
860.30
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Feb 13, 15:58Prev. Close
865.75
Open Price
867.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
857.65 (27)
| Cash Flow of Strides Pharma Science (in Rs. Cr.) | Mar 15 | Mar 14 | Dec 12 | Dec 11 | Dec 10 | |
| 12 mths | 15 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 669.03 | 4,611.95 | 59.89 | 126.18 | 89.08 | |
| Net CashFlow From Operating Activities | 207.39 | -3.35 | 12.12 | 101.69 | 56.25 | |
| Net Cash Used In Investing Activities | 304.95 | 3,998.54 | 898.00 | -3.83 | -355.85 | |
| Net Cash Used From Financing Activities | -802.21 | -3,497.98 | -962.19 | -92.83 | 347.15 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 1.92 | -3.34 | 0.37 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | -289.87 | 497.21 | -50.14 | 1.70 | 47.93 | |
| Cash And Cash Equivalents Begin of Year | 515.69 | 18.48 | 69.07 | 67.37 | 19.23 | |
| Cash And Cash Equivalents End Of Year | 225.82 | 515.69 | 18.93 | 69.07 | 67.16 |
03.02.2026
Strides Pharma Consolidated December 2025 Net Sales at Rs 1,194.65 crore, up 3.55% Y-o-Y
03.02.2026
Strides Pharma Standalone December 2025 Net Sales at Rs 553.63 crore, up 0.49% Y-o-Y
26.12.2025
10.11.2025
Strides Pharma Standalone September 2025 Net Sales at Rs 522.15 crore, down 14.4% Y-o-Y
03.02.2026
Strides Pharma Consolidated December 2025 Net Sales at Rs 1,194.65 crore, up 3.55% Y-o-Y
03.02.2026
Strides Pharma Standalone December 2025 Net Sales at Rs 553.63 crore, up 0.49% Y-o-Y
10.11.2025
Strides Pharma Standalone September 2025 Net Sales at Rs 522.15 crore, down 14.4% Y-o-Y
31.10.2025
Strides Pharma Consolidated September 2025 Net Sales at Rs 1,220.83 crore, up 1.64% Y-o-Y
12.04.2021
Strides Pharma Science Q4 PAT may dip 488.7% YoY to Rs. 72.3 cr: Sharekhan
12.04.2018
Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key
18.01.2018
Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key
17.08.2016